Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia
Open accessThe DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Glucagon and glucagon-like peptide (GLP)-1 are the primary products of proglucagon processing from the pancreas and gut, respectively. Giving dual agonists with glucagon and GLP-1 activity to diabetic, obese mice causes enhanced weight loss and improves glucose tolerance by reduction of food intake and by increase in energy expenditure (EE). We aimed to observe the effect of a combination of glucagon and GLP-1 on resting EE and glycemia in healthy human volunteers. In a randomized, double-blinded crossover study, 10 overweight or obese volunteers without diabetes received placebo infusion, GLP-1 alone, glucagon alone, and GLP-1 plus glucagon simultaneously. Resting EE—measured using indirect calorimetry—was not affected by GLP-1 infusion but rose significantly with glucagon alone and to a similar degree with glucagon and GLP-1 together. Glucagon infusion was accompanied by a rise in plasma glucose levels, but addition of GLP-1 to glucagon rapidly reduced this excursion, due to a synergistic insulinotropic effect. The data indicate that drugs with glucagon and GLP-1 agonist activity may represent a useful treatment for type 2 diabetes and obesity. Long-term studies are required to demonstrate that this combination will reduce weight and improve glycemia in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Besides, small-scale studies support the ability of glucagon receptor activation to increase metabolic rate in both fed and fasted conditions, making the glucagoneglucagon receptor axis an attractive therapeutic approach to combine with anti-obesity medications that work by reducing caloric intake (Nair, 1987;Tan et al, 2013;Salem et al, 2016;Stahel et al, 2019).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Tan et al, 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite glucagon’s blood sugar-increasing effect, glucagon receptor activation moderates food intake, enhances fatty acid breakdown, and increases energy expenditure, supporting the rational use of glucagon in combination with other incretin hormones in the treatment of obesity and T2DM [34].”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [34]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Subsequent studies revealed that co-infusion of GLP-1 with GCG can mitigate the GCG-induced hyperglycaemia [34], while preserving GCG’s metabolic benefits”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [34]
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, the combination of glucagon with GLP-1 actions could improve WL while protecting against the risk of hyperglycaemia [64].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [64]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“These trials have more or less uniformly demonstrated a benefit, with lifestyle more efficacious than all medications with the exception of the thiazolidinediones140–152.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [142]
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 44 · Cited by 258
Metadata
- Authors
- Tan, T. M., Field, B. C. T., McCullough, K. A., Troke, R. C., Chambers, E. S., Salem, V., Gonzalez Maffe, J., Baynes, K. C. R., De Silva, A., Viardot, A., Alsafi, A., Frost, G. S., Ghatei, M. A., & Bloom, S. R.
- Affiliations
- Imperial College London (GB)
- Imperial Clinical Trials Unit, Imperial College London, London, U.K.
- Section of Investigative Medicine, Imperial College London, London, U.K.
- Corresponding author
- Bloom, Stephen R.
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2013-03-14
- Volume
- 62
- Issue
- 4
- Pages
- 1131-1138
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3609580
- OpenAlex
- W2148623180
- Cited by
- 258
- References
- 44
- Citations by year
- 2026: 13 · 2025: 19 · 2024: 30 · 2023: 28 · 2022: 20 · 2021: 18 · 2020: 15 · 2019: 17 · 2018: 25 · 2017: 16 · 2016: 13 · 2015: 20 · 2014: 13 · 2013: 11
- FWCI
- 11.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Imperial College Healthcare Charity
- National Institute for Health and Care Research (FP7-HEALTH-2009-241592, NF-SI-0508-10112)
- Imperial College London
- Imperial College Healthcare NHS Trust
- Directorate for Biological Sciences
- Medical Research Council (FP7-HEALTH-2009-241592)
- Biotechnology and Biological Sciences Research Council (FP7-HEALTH-2009-241592 EuroCHIP, FP7-HEALTH-2009-241592)
- NIHR Imperial Biomedical Research Centre
- FP7 Health (2009-241592 EuroCHIP)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- glucagon-like peptide-1, glucagon, co-administration, energy expenditure, hyperglycemia, insulinotropic effect, proglucagon, obesity, type 2 diabetes, glucose tolerance, weight loss
- MeSH terms
- Adult, Calorimetry, Indirect, Double-Blind Method, Energy Metabolism, Female, Glucagon, Humans, Hyperglycemia, Infusions, Intravenous, Male, Middle Aged, Cross-Over Studies, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia. https://app.cochat.ai/papers/10.2337/db12-0797
- The paper
- Tan, T. M., Field, B. C. T., McCullough, K. A., Troke, R. C., Chambers, E. S., Salem, V., Gonzalez Maffe, J., Baynes, K. C. R., De Silva, A., Viardot, A., Alsafi, A., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2013). Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia. Diabetes. https://doi.org/10.2337/db12-0797
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.